The Food and Drug Administration issued an alert about a "potentially high-risk issue" regarding malfunctioning Abbott glucose sensors that have been linked to more than 700 serious injuries and 7 ...

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

Abbott Laboratories shares dipped after announcing a $23 billion acquisition of Exact Sciences, citing concerns over the deal premium and future dilution. Abbott's diversified business, strong organic ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott Laboratories ABT1.77%increase; green up pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.14%increase; green up pointing triangle in a deal valued at about ...

Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp, Bloomberg News reported on Wednesday, citing people familiar with the matter. The ...

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

The acquisition will allow the diagnostics giant to enter the rapidly growing market for cancer tests Exact Sciences sells Cologuard, the at-home test for colorectal cancer that allows some patients ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Abbott said Thursday it would buy Exact Sciences, the maker of tests ...